Description: Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
Home Page: www.chugai-pharm.co.jp
2-1-1 Nihonbashi-Muromachi
Chuo,
103-8324
Japan
Phone:
81 3 3281 6611
Officers
| Name | Title |
|---|---|
| Dr. Osamu Okuda | President, CEO & Chairman |
| Mr. Iwaaki Taniguchi | Executive VP, Head of Finance Supervisory Division, CFO & Director |
| Toshiya Sasai | Executive of Investor Relations Group & Corporate Communications Department |
| Mr. Masayoshi Higuchi | VP and Head of Quality, Regulatory Compliance Unit, Business Strategy & Compliance Dept. |
| Junichi Takano | Head of Marketing & Sales Division |
| Mr. Shinji Hidaka | Executive Vice President |
| Mr. Junichi Ebihara | Executive Vice President |
| Dr. Yoshiaki Ohashi | Senior VP & Full-time Audit Supervisory Board Member |
| Mr. Tetsuya Yamaguchi | Executive VP & Head of PHC Solution Unit |
| Mr. Yoshiyuki Yano | Executive Vice President |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 26.1097 |
|---|---|
| Trailing PE: | 28.1014 |
| Price-to-Book MRQ: | 6.2122 |
| Price-to-Sales TTM: | 0.0616 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 7604 |